Antimicrobial resistance in Helicobacter pylori

Reviews and Research in Medical Microbiology

Volumn 12, Issue 1, 2001, Pages 47-61

  Canton R ^a   Martin de Argila C ^a   De Rafael, L ^a   Baquero, F ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Antimicrobial resistances; Helicobacter pylori; Sceptibility testing

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; METRONIDAZOLE; NITRATE REDUCTASE; NITROIMIDAZOLE; PENICILLIN BINDING PROTEIN; PEPTIDYLTRANSFERASE; PROTON PUMP INHIBITOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; RNA 23S; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CHRONIC GASTRITIS; DRUG TOLERANCE; ERADICATION THERAPY; GENE MUTATION; HELICOBACTER PYLORI; HUMAN; PEPTIC ULCER; PRIORITY JOURNAL; RIBOSOME SUBUNIT; STOMACH CARCINOMA; STOMACH LYMPHOMA;

EID: 0035139088     PISSN: 0954139X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00013542-200101000-00006     Document Type: Article

References (79)

1. Helicobacter pylori infection
2. Recurrence of duodenal ulcer and Campylobacter pylori infection after eradication
3. Treatment of Helicobacter pylori infection
4. Compliance adverse events and antibiotic resistance in Helicobacter pylori treatment
5. Aspectos microbiologicos de Helicobacter pylori
6. Resistance of Helicobacter pylori to antibiotics
7. Setting the standard for determining the in vitro susceptibility of Helicobacter pylori to metronidazole
8. Direct detection of Helicobacter pylori resistance to macrolides by polymerase chain reaction/DNA enzyme inmmunoassay in gastric biopsy specimens
9. Isolation and characterization of a family of porin proteins from Helicobacter pylori
10. Competition of various β-lactam antibiotics for the major penicillin-binding proteins of Helicobacter pylori: Antibacterial activity and effects on bacterial morphology
11. Helicobacter pylori uptake and efflux: Basis for intrinsic susceptibility to antibiotics in vitro
12. Helicobacter pylori
13. Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori
14. Metronidazole resistance in H. pylori is due to null mutations in a gene (rdxA) that encodes an oxygen-insensitive NADPH nitroreductase
15. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection
16. In vitro selection of resistant H. pylori
17. Growth characteristics and influence of antibiotics on rough/smooth phenotypic variants of Helicobacter pylori
18. Evolution of Helicobacter pylori: The role of recombination
19. Insertion of mini-IS605 and deletion of adjacent sequences in the nitroreductase (rdxA) gene cause metronidazole resistance in Helicobacter pylori
20. Drug therapy for Helicobacter pylori infection: Problems and pitfalls
21. What can we learn from the new data about antibiotic resistance? Are there any practical clinical consequences of Helicobacter pylori antibiotic resistance?
22. In vitro studies on stability and development of metronidazole resistance in Helicobacter pylori
23. Activities of b-lactams and macrolides against Helicobacter pylori
24. Bactericidal and morphological effects of amoxicillin on Helicobacter pylori
25. Gastric penetration of amoxicillin in a human Helicobacter pylori-infected xenograft model
26. Amoxycillin resistance is one reason for failure of amoxycillin-omeprazole treatment of Helicobacter pylori infection
27. Stable amoxicillin resistance in Helicobacter pylori
28. Different penicillin-binding profiles in amoxicillin-resistant Helicobacter pylori
29. Risk of development of in vitro resistance to amoxicillin clarithromycin, and metronidazole in Helicobacter pylori
30. Use of digoxigenin-labelled ampicillin in the identification of penicillin-binding proteins in Helicobacter pylori
31. Amoxicillin tolerance in Helicobacter pylori
32. Cloning and sequences analysis of two copies of a 23S rRNA gene from Helicobacter pylori and association of clarithromycin resistance with 23S rRNA mutations
33. Site-specific mutations in the 23S rRNA gene of Helicobacter pylori confer two types of resistance to macrolides-lincosamide-streptogramin B antibiotics
34. Mutations in 23S RNA in Helicobacter pylori conferring resistance to erythromycin do not always confer resitance to clarithromycin
35. Multiplex sequence analysis demonstrated the competitive growth advantage of the G-to-A mutants of clarithromycin-resistant Helicobacter pylori
36. Simultaneous colonisation of Helicobacter pylori with and without mutations in the 23S rRNA gene in patients with no history of clarithromycin exposure
37. Metronidazole uptake in Helicobacter pylori
38. In vitro studies on stability and development of metronidazole resistance in Helicobacter pylori
39. Frequent association between alteration of the rdxA gene and metronidazole resitance in French and north African isolates of Helicobacter pylori
40. Isolation of a genetic locus associated with metronidazole resistance in Helicobacter pylori
41. In vivo acquired resistance to fiuoroquinolones in Helicobacter pylori during therapy with ciprofloxacin or ciprofloxacin plus amoxicillin/clavulanate
42. Nucleotide sequence of the gyrA gene and characterization of ciprofloxacin-resistant mutant of Helicobacter pylori
43. Helicobacter pylori resistance to tetracycline
44. The epidemiology of Helicobacter pylori antimicrobial resistace - Preliminary findings of a national survey
45. Rifampin and rifabutin resistance mechanism in Helicobacter pylori
46. Mutations in the beginning of the rpoB gene can induce resistance to rifamycins in both Helicobacter pylori and Mycobacterium tuberculosis
47. Mutations at four distinct regions of the rpoB gene can reduce the susceptibility of Helicobacter pylori to rifamycins
48. Bismuth-mediated disruption of the glycocalyx-cell wall Helicobacter pylori: Ultrastructural evidence for a mechanism of action for bismuth salts
49. Role of Hpn and NixA of Helicobacter pylori in susceptibility and resistance to bismuth and other metal ions
50. Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: The MACH study
51. Eradication of Helicobacter pylori using one week triple therapies combining omeprazole with two antimicrobials: The MACH 1 study
52. Antibiotic resistance problems with Helicobacer pylori
53. Metronidazole and clarithromycin resistance amongst Helicobacter pylori isolates from a large metropolitan hospital in the United States
54. Prevalence of primary resistance to metronidazole and clarithromycin in The Netherlands
55. Characteristics and trends in macrolide resistance among Helicobacter pylori strains isolated in Bulgaria over four years
56. Prevalence of Helicobacter pylori resistance to several antimicrobial agents in a region of Germany
57. Survey of the in vitro susceptibility of Helicobacter pylori to antibiotics in France
58. Antimicrobial resistance and Helicobacter pylori
59. Antibiotic resistance in Helicobacter pylori: Implications for therapy
60. Impact of clarithomycin resistance on the effectiveness of a regimen for Helicobacter pylori: A prospective study of 1-week lansoprazole, amoxycillin and clarithromycin in active peptic ulcer
61. Clinical relevance of resistant strains of Heticobacter pylori: A review of current data
62. Relevance of antibiotic sensitivities in predicting failure of omeprazole, clarithromycin, and tinidazole to eradicate Helicobacter pylori
63. Antimicrobial susceptibility testing of Helicobacter pylori. Comparison of E-test, broth microdilution, and disk diffusion for ampicillin, clarithromycin, and metronidazole
64. Standardization of disk diffusion test and its clinical significance for susceptibility testing of metronidazole against Helicobacter pylori
65. Metronidazole-and clarithromycin-resistant Helicobacter pylori in dyspeptic patients in western Sydney as determined by testing multiple isolates from different gastric sites
66. Validation of a modified Kirby-Bauer disk difussion method for metronidazole susceptibility testing of Helicobacter pylori
67. A systematic review of Helicobacter pylori eradication therapy - The impact of antimicrobial resistance on eradication rates
68. Metronidazole resistance reduces efficacy of triple therapy and leads to secondary clarithromycin resistance
69. Susceptibility of Helicobacter pylori isolates to metronidazole, clarithromycin and amoxicillin in vitro and in clinical treatment in Japan
70. Treatment after failure: The problem of 'non-responders'
71. The importance of clarithromycin dose in the management of Helicobacter pylori infection: A meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxicillin or metronidazole
72. The Report of the Digestive Health Intiative International Update Conference on Helicobacter pylori
73. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report
74. Choosing the best anti-Helicobacter pylori therapy: Effect of antimicrobial resistance
75. How to treat H. pylori infection. Should treatment strategies be based on bacterial susceptibility? A personal viewpoint
76. Failure of Helicobacter pylori eradication in an ambulatory population: Is poor compliance the main cause?
77. Importance of Helicobacter pylori cagA and vacA status for the efficacy of antibiotic treatment
78. Extra-digestive manifestations of Helicobacter pylori infection. Science or fiction?